Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Diatabs Advance - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Diatabs Advance

Approved

STANDARD

Diatabs Advance

Amherst Laboratories, Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 829878db45fc042a
Company: Amherst Laboratories, Inc.
Type: Standard

Approval Details

Approval Id: 829878db45fc042a
Drug Approval Philippines Name: Diatabs Advance
Product Name: Diatabs Advance
Registration Number: DR-XY46907
Brand Name: Diatabs Advance
Generic Name: Loperamide + Simeticone
Dosage Form: Softgel Capsule
Dosage Strength: 2 mg/125 mg
Manufacturer: Amherst Laboratories, Inc.
Trader: Unilab, Inc.
Issuance Date: 27 September 2024
Expiry Date: 17 December 2030
Pharmacologic Category: Antidiarrheal / Antiflatulent
Classification: Over-The-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

829878db45fc042a

Type

Standard

Back to Philippines FDA Approvals